Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/105416
Título: | Reducing oral corticosteroids in severe asthma (ROSA Project): a nationwide Portuguese consensus | Autor: | Loureiro, Cláudia Chaves Branco Ferreira, Manuel Ferreira, Jorge Lima, Ricardo Marques, João Sokolova, Anna Tonin, Fernanda S. Duarte Ramos, Filipa |
Palavras-chave: | Asthma; Oral corticosteroids; Delphi panel; Consensus | Data: | 2021 | Editora: | Elsevier Espana S.L.U | Projeto: | AstraZeneca | Título da revista, periódico, livro ou evento: | Pulmonology | Volume: | 27 | Número: | 4 | Resumo: | Introduction and objectives: We aimed to build a national consensus to optimize the use of oral corticosteroids (OCS) in severe asthma in Portugal. Material and methods: A modified 3-round Delphi including 65 statements (topics on chronic systemic corticotherapy, therapeutic schemes, asthma safety and monitoring) was performed via online platform (October-November 2019). A five-point Likert-type scale was used (1- ‘strongly disagree’; 5-‘strongly agree’). Consensus threshold was established as a percentage of agreement among participants ≥90% in the 1st round and ≥85% in the 2nd and 3rd rounds. The level of consensus achieved by the panel was discussed with the participants (face-to-face meeting). Results: Forty-eight expert physicians in severe asthma (specialists in allergology and pulmonology) participated in the study. Almost half of the statements (28/65; 43.1%) obtained positive consensus by the end of round one. By the end of the exercise, 12 (18.5%) statements did not achieve consensus. Overall, 87% of physicians agree that further actions for OCS cumu-lative risk assessment in acute asthma exacerbations are needed. The vast majority (91.7%)demonstrated a favorable perception for using biological agents whenever patients are eligible.Most participants (95.8%) are more willing to accept some degree of lung function deteriorationcompared to other outcomes (worsening of symptoms, quality of life) when reducing OCS dose.Monitoring patients’ comorbidities was rated as imperative by all experts.Conclusions: : These results can guide an update on asthma management in Portugal and shouldbe supplemented by studies on therapy access, patients’ adherence, and costs. | URI: | https://hdl.handle.net/10316/105416 | ISSN: | 25310437 | DOI: | 10.1016/j.pulmoe.2020.10.002 | Direitos: | openAccess |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
1-s2.0-S2531043720302178-main.pdf | 750.05 kB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
6
Visto em 26/ago/2024
Citações WEB OF SCIENCETM
4
Visto em 2/ago/2024
Visualizações de página
77
Visto em 27/ago/2024
Downloads
47
Visto em 27/ago/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons